Conclusions
HeFH
DISEASE
In summary, tafolecimab dosed 150 mg Q2W and 450 mg Q4W demonstrated robust and persistent lipid-lowering efficacy in Chinese patients with HeFH. Participants on tafolecimab achieved a 12-week reduction in LDL-C levels around 60% and were significantly more likely to attain ≥50% LDL-C reductions and LDL-C<1.8 mmol/L. Together with the favorable safety profile, tafolecimab may offer HeFH patients a novel treatment option for effective disease control.